万维提示：
1、投稿方式：在线投稿。
2、期刊网址：
https://journals.lww.com/retinajournal/pages/default.aspx
3、投稿网址：
http://www.editorialmanager.com/retina/default.aspx
4、官网邮箱：retina@retinajournal.com
5、期刊刊期：月刊，一年出版12期。
2021年6月1日星期二
投稿须知【官网信息】
Author Resources
Scope: RETINA, The Journal of Retinal and Vitreous Diseases, publishes original and special articles concerning disorders of the retina and vitreous.
Ethical/Legal Considerations. A submitted manuscript must be an original contribution not previously published (except as an abstract or preliminary report), must not be under consideration for publication elsewhere, and if accepted, it must not be published elsewhere in similar form, in any language, without the consent of Lippincott Williams & Wilkins. Each person listed as an author is expected to have participated in the study to a significant extent. Although the editors and referees make every effort to ensure the validity of published manuscripts, the final responsibility rests with the authors, not with the Journal, its editors, or the publisher. All manuscripts must be submitted on-line through the journal’s Web site at www.retinajournal.com. See submission instructions under "On-line manuscript submission."
Financial Disclosure. Each author warrants that he or she has no commercial associations (e.g., consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article, except as disclosed on a separate attachment. All funding sources supporting the Work and all institutional or corporate affiliations of the authors are acknowledged in a footnote in the Work and on the Copyright/Financial Disclosure form that is requested upon acceptance.
Patient anonymity and informed consent. It is the author's responsibility to ensure that a patient's anonymity be carefully protected and to verify that any experimental investigation with human subjects reported in the manuscript was performed with informed consent and following all the guidelines for experimental investigation with human subjects required by the institution(s) with which all the authors are affiliated. Authors should mask patients' eyes and remove patients' names from figures unless they obtain written consent from the patients and submit written consent with the manuscript.
Questions? Contact the Editorial Office at retina@retinajournal.com.
Compliance with NIH and Other Research Funding Agency Accessibility Requirements
A number of research funding agencies now require or request authors to submit the post-print (the article after peer review and acceptance but not the final published article) to a repository that is accessible online by all without charge. As a service to our authors, LWW will identify to the National Library of Medicine (NLM) articles that require deposit and will transmit the post-print of an article based on research funded in whole or in part by the National Institutes of Health, Wellcome Trust, Howard Hughes Medical Institute, or other funding agencies to PubMed Central. The revised Copyright Transfer Agreement provides the mechanism.
Copyright. In view of the Copyright Revision Act of 1976, effective January 1, 1978, all transmittal letters must contain the following language before manuscripts can be reviewed for possible publication:
"In consideration of the journal RETINA® taking action in reviewing and editing my (our) submission, which represents an original article (the copyright of which is held solely by the undersigned), the author(s) undersigned hereby transfers, assigns, or otherwise conveys all copyright ownership to the Ophthalmic Communications Society, Inc. in the event that such work is published in the journal RETINA®. Manuscripts authored by US government employees are exempted from the requirement of the preceding paragraph if they constitute works of the US government. Under copyright law, a work of authorship prepared by an officer or employee of the US government as part of that person's official duties is in the public domain and is not subject to copyright protection. All manuscripts constituting such works that are submitted to RETINA®(or their accompanying transmittal letters) should not contain the language quoted in the preceding sentences, but must contain the following language instead, accompanied by the signature(s) of the author(s), before they can be considered for possible publication: "The submitted manuscript is a work of authorship prepared as part of my (our) official duties as an officer or employee of the US government and is therefore in the public domain."
Submission to and/or Rejection by Other Journals. If the manuscript was previously submitted to and/or rejected by another journal, authors must provide the journal name and decision date on the online submission form. Authors should also prepare and submit copies of any reviewers’ comments and responses within the Cover Letter.
OPEN ACCESS
LWW's hybrid open access option is offered to authors whose articles have been accepted for publication. With this choice, articles are made freely available online immediately upon publication. Authors may take advantage of the open access option at the point of acceptance to ensure that this choice has no influence on the peer review and acceptance process. These articles are subject to the journal's standard peer-review process and will be accepted or rejected based on their own merit.
Authors of accepted peer-reviewed articles have the choice to pay a fee to allow perpetual unrestricted online access to their published article to readers globally, immediately upon publication. The article processing charge for Retina, the Journal of Retinal and Vitreous Diseases, is $3,100. The article processing charge for authors funded by the Research Councils UK (RCUK) is $3,900. The publication fee is charged on acceptance of the article and should be paid within 30 days by credit card by the author, funding agency or institution. Payment must be received in full for the article to be published open access. Any additional standard publication charges, such as for color images, will also apply.
Authors retain copyright
Authors retain their copyright for all articles they opt to publish open access. Authors grant LWW a license to publish the article and identify itself as the original publisher.
In addition, each author must complete and submit the journal’s copyright transfer agreement, which includes a section on the disclosure of potential conflicts of interest based on the recommendations of the International Committee of Medical Journal Editors, “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” (www.icmje.org/update.html).
A copy of the form is made available to the submitting author within the Editorial Manager submission process. Co-authors will automatically receive an Email with instructions on completing the form upon submission.
Creative Commons license
Articles opting for open access will be freely available to read, download and share from the time of publication. Articles are published under the terms of the Creative Commons License Attribution-Non Commerical No Derivative 3.0 which allows readers to disseminate and reuse the article, as well as share and reuse of the scientific material. It does not permit commercial exploitation or the creation of derivative works without specific permission. To view a copy of this license visit: http://creativecommons.org/licenses/by-nc-nd/3.0.
Compliance with NIH, RCUK, Wellcome Trust and other research funding agency accessibility requirements
A number of research funding agencies now require or request authors to submit the post-print (the article after peer review and acceptance but not the final published article) to a repository that is accessible online by all without charge. As a service to our authors, LWW identifies to the National Library of Medicine (NLM) articles that require deposit and transmits the post-print of an article based on research funded in whole or in part by the National Institutes of Health, Howard Hughes Medical Institute, or other funding agencies to PubMed Central. The revised Copyright Transfer Agreement provides the mechanism. LWW ensures that authors can fully comply with the public access requirements of major funding bodies worldwide. Additionally, all authors who choose the open access option will have their final published article deposited into PubMed Central.
RCUK and Wellcome funded authors can choose to publish their paper as open access with the payment of an article process charge (gold route), or opt for their accepted manuscript to be deposited (green route) into PMC with an embargo.
With both the gold and green open access options, the author will continue to sign the Copyright Transfer Agreement (CTA) as it provides the mechanism for LWW to ensure that the author is fully compliant with the requirements. After signature of the CTA, the author will then sign a License to Publish where they will then own the copyright. Those authors who wish to publish their article via the gold route will be able to publish under the terms of the Attribution 3.0 (CCBY) License. To view of a copy of this license visit:http://creativecommons.org/licenses/by/2.0/. Those authors who wish to publish their article via the green route will be able to publish under the rights of the Attribution Non-commercial 3.0 (CCBY NC) license (http://creativecommons.org/licenses/by-nc/2.0/).
It is the responsibility of the author to inform the Editorial Office and/or LWW that they have RCUK funding. LWW will not be held responsible for retroactive deposits to PMC if the author has not completed the proper forms.
FAQ for open access
http://links.lww.com/LWW-ES/A48
Permissions. Authors must submit written permission from the copyright owner (usually the publisher) to use direct quotations, tables, or illustrations that have appeared in copyrighted form elsewhere, along with complete details about the source. Any permissions fees that might be required by the copyright owner are the responsibility of the authors requesting use of the borrowed material, not the responsibility of Lippincott Williams & Wilkins.
For permission and/or rights to use content for which the copyright holder is LWW or the society, please go to the journal's website and after clicking on the relevant article, click on the "Request Permissions" link under the "Article Tools" box that appears on the right side of the page. Alternatively, send an e-mail to customercare@copyright.com.
For Translation Rights & Licensing queries, contact Silvia Serra, Translations Rights, Licensing & Permissions Manager, Wolters Kluwer Health (Medical Research) Ltd, 250 Waterloo Road, London SE1 8RD, UK. Phone: +44 (0) 207 981 0600. E-mail: silvia.serra@wolterskluwer.com
For Special Projects and Reprints (U.S./Canada), contact Alan Moore, Director of Sales, Lippincott Williams & Wilkins, Two Commerce Square, 2001 Market Street, Philadelphia, PA 19103. Phone: 215-521-8638. E-mail: alan.moore@wolterskluwer.com
For Special Projects and Reprints (non-U.S./Canada), contact Silvia Serra, Translations Rights, Licensing & Permissions Manager, Wolters Kluwer Health (Medical Research) Ltd, 250 Waterloo Road, London SE1 8RD, UK. Phone: +44 (0) 207 981 0600. E-mail: silvia.serra@wolterskluwer.com
Manuscript Submission
On-line manuscript submission. All manuscripts must be submitted on-line through the Web site: www.retinajournal.com. First-time users: Please click the Register button from the menu and enter the requested information. On successful registration, you will be sent an e-mail indicating your user name and password. Print a copy of this information for future reference. Note: If you have received an e-mail from us with an assigned user ID and password, or if you are a repeat user, do not register again. Just log in. Once you have an assigned ID and password, you do not have to re-register, even if your status changes (that is, author, reviewer, or editor).
Authors: Please click the log-in button from the menu at the top of the page and log into the system as an Author. Submit your manuscript according to the author instructions. You will be able to track the progress of your manuscript through the system. If you experience any problems, please contact us either by e-mail at retina@retinajournal.com or 610-525-4849.
PREPARATION OF MANUSCRIPTS
Manuscripts that do not adhere to the following instructions will be returned to the corresponding author for technical revision before undergoing peer review. The manuscript/text part of your submission must be in WORD (.DOC or .DOCX format)
A complete list of our article types and special instructions for manuscript preparations are listed below. Additionally, their reference list limits are provided in the table below. Exemptions to these limits will not be permitted.
Please see the table below for detailed instructions concerning the word count for abstracts and manuscript text, number of references, and number of figures and tables for specific types of articles submitted to this journal.
……
更多详情：
http://edmgr.ovid.com/retina/accounts/ifauth.htm
